An Overview of Scarring Alopecias

Scarring alopecias, sometimes also known as cicatricial alopecias, represent a heterogeneous group of disorders that result in irreversible hair loss due to the destruction of hair follicles. Scarring alopecias almost always involve inflammation of the hair follicles and, if it is left untreated, the inflammation eventually destroys the hair follicles. This type of permanent hair loss can arise from either primary or secondary processes. In primary cicatricial alopecias, the hair follicle itself is the direct target of the inflammatory disease, leading to its destruction and subsequent scarring. In contrast, secondary cicatricial alopecias occur as a consequence of a more generalized disease process affecting multiple tissues and organs where hair follicles get caught in the crossfire.

Primary Cicatricial Alopecias: Primary scarring alopecias are characterized by the destruction of the hair follicles and loss of follicular ostia, the openings of the hair follicles through which hair fibers emerge. These disorders specifically target hair follicles without involving other tissues or organs. The initial stages of primary cicatricial alopecias are usually non-scarring, which can sometimes make early diagnosis challenging. Patients often present with reddish inflamed areas and lesions on the scalp, which eventually lead to irregular bald patches amidst areas of normal to sparse hair growth. As the disease progresses, these patches enlarge, leading to a more pronounced receding hair growth pattern and potentially extensive scalp baldness in the absence of any treatment.

Classification Systems: The classification of primary scarring alopecias has evolved over time, with various methods based on age of onset, clinical features, and pathological findings. The most widely accepted classification system among dermatologists is that of the American Hair Research Society (AHRS). This system categorizes primary cicatricial alopecias based on the predominant inflammatory cell type observed in scalp biopsy specimens from active lesions. The three main categories are:

1. Lymphocytic Cicatricial Alopecias: These disorders are characterized by lymphocytic infiltration around the hair follicles. Examples include:
   • Lichen Planopilaris (LPP): A common form of lymphocytic scarring alopecia, LPP presents with perifollicular erythema, hyperkeratosis, and pruritus. The disease often progresses slowly, but it can lead to significant hair loss over time.
   • Chronic Cutaneous Lupus Erythematosus (CCLE): Also known as discoid lupus erythematosus (DLE), CCLE manifests as well-defined, erythematous, and scaly plaques that can lead to scarring and permanent hair loss.
   • Frontal Fibrosing Alopecia (FFA): Possibly a variant of LPP, FFA primarily affects postmenopausal women and is characterized by a band-like recession of the frontal hairline. There can also be eyebrow loss.
2. Neutrophilic Cicatricial Alopecias: These are less common and involve neutrophilic cell infiltration. Examples include:
   • Folliculitis Decalvans: Presents with pustules, crusts, and tufted hair follicle units. It often leads to scarring and hair loss.
   • Dissecting Cellulitis of the Scalp: Also sometimes known as perifolliculitis capitis abscedens et suffodiens, this condition presents with painful nodules, abscesses, and draining sinus tracts, eventually leading to scarring alopecia.
3. Mixed or Non-Specific Cicatricial Alopecias: Disorders that do not fit neatly into the lymphocytic or neutrophilic categories are classified as mixed or non-specific. These include:
   • Central Centrifugal Cicatricial Alopecia (CCCA): Predominantly affects women of African descent and presents with a progressive, symmetrical alopecia that starts at the vertex and spreads centrifugally.
   • Alopecia Mucinosa: Characterized by follicular papules and plaques, which can lead to scarring and hair loss.

Pathogenesis: The exact mechanisms underlying primary cicatricial alopecias remain unclear, but several hypotheses have been proposed. It is believed that genetic predisposition, immune dysregulation, and environmental factors all play a role. The inflammatory process leads to the destruction of the hair follicle stem cells located in the bulge area of the follicle, which are crucial for hair cycling and regeneration. Once these stem cells are destroyed, the hair follicle cannot regenerate during a normal hair cycle, resulting in permanent hair loss and scarring.

Clinical Presentation and Diagnosis: The clinical presentation of primary cicatricial alopecias varies depending on the specific disorder. Common symptoms include pruritus, pain, erythema (skin redness), scaling, and pustules. As the disease progresses, patients may notice hair thinning, bald patches, and eventual scarring of the skin.

Diagnosis typically involves a thorough clinical examination, detailed patient history, and a scalp biopsy. The biopsy is essential for identifying the type of inflammatory infiltrate and confirming the diagnosis. Dermoscopy can also be a useful tool in evaluating hair and scalp changes, such as the presence of follicular plugging, perifollicular scaling, and loss of follicular openings.

Epidemiology: Scarring alopecias, or cicatricial alopecias, while relatively rare, represent a significant clinical concern due to their irreversible nature. The epidemiology of these disorders is not as well-documented as non-scarring forms of alopecia, largely due to their heterogeneity and the challenges in early diagnosis. However, certain trends and demographic patterns have been observed:

• Prevalence: The exact prevalence of scarring alopecias varies across different studies and with different types of alopecia, but they are generally considered uncommon. For instance, lichen planopilaris (LPP), a relatively common form of lymphocytic scarring alopecia, has an estimated prevalence of about 1.15 per 100,000 individuals.
• Gender Differences: Many forms of scarring alopecia exhibit a gender bias. For example, frontal fibrosing alopecia (FFA) predominantly affects postmenopausal women, while conditions like folliculitis decalvans have a higher prevalence in men.
• Age of Onset: The age of onset varies depending on the specific type of scarring alopecia. FFA typically presents in middle-aged to older women, whereas LPP can affect adults of various ages. Central centrifugal cicatricial alopecia (CCCA) often presents in women of African descent in their middle age.
• Variations with Ethnicity: There are notable ethnic variations in the prevalence of scarring alopecias. CCCA, for example, is most commonly seen in women of African descent. This suggests a potential genetic predisposition. The influence of cultural and environmental factors might also be involved, but recent research points more towards genetics.

Treatment: The primary goal of treatment for scarring alopecias is to halt the progression of the disease and prevent further hair loss. Early intervention is vital, as once hair follicles are destroyed, regrowth is not possible. Treatment strategies vary depending on the type of cicatricial alopecia and the severity of the disease. Commonly used treatments include:

• Topical and Systemic Corticosteroids: These are often the first-line treatment to reduce inflammation and suppress the immune response.
• Antimalarials: Drugs such as hydroxychloroquine are sometimes used, particularly in lymphocytic cicatricial alopecias like LPP and CCLE.
• Immunosuppressive Agents: Medications such as methotrexate, mycophenolate mofetil, and cyclosporine may be used in more severe or refractory cases. More recently, dermatologists have been investigating the use of JAK inhibitors to treat scarring alopecias.
• Antibiotics: Tetracyclines and other antibiotics with anti-inflammatory properties can be beneficial in neutrophilic cicatricial alopecias.
• Biologic Agents: Targeted biologic therapies, such as TNF inhibitors and IL-17 inhibitors, are being explored as potential treatments for scarring alopecias.

Recent Advances and Research: Recent research has provided new insights into the pathogenesis and potential treatment options for scarring alopecias. Advances in genetic studies have identified potential susceptibility genes, while immunological research has elucidated some of the complex interplay between the immune system and hair follicles – though there is still much that is not understood about scarring alopecia development. Additionally, novel therapeutic approaches, including JAK inhibitors and other targeted therapies, are being investigated for their potential to halt disease progression and promote hair regrowth.

Conclusion: Scarring alopecias are a diverse group of disorders characterized by irreversible hair loss due to the destruction of hair follicles. Early diagnosis and intervention are essential to prevent extensive hair loss and scarring. Advances in research are improving our understanding of these complex disorders and paving the way for more effective treatments. Continued research is important to uncover the underlying mechanisms and develop targeted therapies that can improve outcomes for patients with scarring alopecias.

Bibliography